Affordable Access

deepdyve-link
Publisher Website

MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin.

Authors
  • Kaitu'u-Lino, Tu'uhevaha J1
  • Palmer, Kirsten R
  • Whitehead, Clare L
  • Williams, Elizabeth
  • Lappas, Martha
  • Tong, Stephen
  • 1 Translational Obstetrics Group, Mercy Hospital for Women, University of Melbourne, Heidelberg, Australia. , (Australia)
Type
Published Article
Journal
American Journal Of Pathology
Publisher
Elsevier
Publication Date
Mar 01, 2012
Volume
180
Issue
3
Pages
888–894
Identifiers
DOI: 10.1016/j.ajpath.2011.11.014
PMID: 22296769
Source
Medline
License
Unknown

Abstract

Soluble endoglin is an anti-angiogenic protein that is released from the placenta and contributes to both maternal endothelial dysfunction and the clinical features of severe preeclampsia. The mechanism through which soluble endoglin is released from the placenta is currently unknown; however, recent work in colorectal cancer identified matrix metalloproteinase 14 (MMP-14) as the cleavage protease of endoglin. To determine whether this is also the mechanism responsible for soluble endoglin release in preeclampsia, we investigated the expression of MMP-14 within the placenta and the effects of its inhibition on soluble endoglin release. Placentas were obtained from severe, early onset preeclamptic pregnancies (n = 8) and gestationally matched preterm controls (n = 8). MMP-14 was predominately localized to the syncytiotrophoblast. Results from a proximity ligation assay showed protein interactions between endogenous MMP-14 and endoglin within the preeclamptic placenta. To demonstrate that this interaction produces soluble endoglin, we treated trophoblastic BeWo cells with either a broad-spectrum MMP inhibitor (GM6001) or MMP-14 siRNA. Both treatments produced a decrease in soluble endoglin (P ≤ 0.05). Treatment of mice bearing BeWo xenografts with GM6001 decreased circulating soluble endoglin levels in mouse serum (P ≤ 0.05). These findings indicate that MMP-14 is the likely cleavage protease of endoglin in the setting of preeclampsia. This approach provides a novel method for the development of potential therapeutics to reduce circulating soluble endoglin and ameliorate the clinical features of severe preeclampsia.

Report this publication

Statistics

Seen <100 times